A genome-wide screen for variants influencing certolizumab pegol response in a moderate to severe rheumatoid arthritis population.

A genome-wide screen for variants influencing certolizumab pegol response in a moderate to severe rheumatoid arthritis population.

Show other versions (1)

Certolizumab pegol (CZP) is a PEGylated Fc-free tumor necrosis factor (TNF) inhibitor antibody approved for use in the treatment of rheumatoid arthritis (RA), Crohn's disease, psoriatic arthritis, axial spondyloarthritis and psoriasis. In a clinical trial of patients with severe RA, CZP improve...

Full description

Bibliographic Details
Main Authors: Ian R White, Sarah E Kleinstein, Christophe Praet, Chris Chamberlain, Duncan McHale, Jessica M Maia, Pingxing Xie, David B Goldstein, Thomas J Urban, Patrick R Shea
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2022-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0261165

Internet

https://doi.org/10.1371/journal.pone.0261165

Similar Items